Angelica Kottkamp
Infectious Disease · New York, NYNPI 1295163541
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Bausch & Lomb Americas Inc. accounts for 83.7% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for infectious disease clinicians in NY, where the typical reported total is $190.
Across 2 payments — averaging $74.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$125
- Modernatx, Inc.$24
Across 100 payments — averaging $12,334 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.2M
What the payments were for
- Food & beverage$149100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 1 | $125 |
| Modernatx, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$125
How this compares
$149 in reported general payments places this provider in the 45th percentile of 799 infectious disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 151 | $695,738 |
| JulucaDolutegravir/Rilpivirine | 40 | $134,286 |
| OzempicSemaglutide | 20 | $19,085 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 12 | $15,976 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $13,626 |
| TrulicityDulaglutide | 11 | $9,785 |
| Atrovent HfaIpratropium Bromide | 12 | $5,301 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,700 |
| Levetiracetam | 13 | $783 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $775 |
| Atorvastatin Calcium | 85 | $469 |
| Metoprolol Succinate | 36 | $400 |
| Esomeprazole Magnesium | 22 | $382 |
| Rosuvastatin Calcium | 35 | $315 |
| Omeprazole | 31 | $188 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in New York
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Genovefa PapanicolaouNew York$209K
- Michelle CespedesNew York$125K
- Donald KaminskyNew York$120K
- Judith AbergNew York$104K
- Thomas WalshNew York$98K
- Stuart HaberNew York$73K
- Michael GaisaNew York$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.